EUVIMEDPoznaj EUVIMED
Übersichtsarbeit

Modalities to identify clinically actionable neoantigens

Takamasa Ishino, Yosuke Togashi iD

The FEBS Journal · 2026-08-12

DOI: 10.1111/febs.70701 ↗

At a glance

Übersichtsarbeit in The FEBS Journal, published online on 2026-08-12. Written by Takamasa Ishino and 1 co-authors. Institution: Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan. 125 references. Funded by: Fusion Oriented REsearch for disruptive Science and Technology, Canon Foundation for Scientific Research.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Immune checkpoint inhibitors (ICIs), which restore antitumor immunity mediated by T cells, have caused a paradigm shift in cancer therapy. However, only a subset of patients achieve durable clinical responses, highlighting the need to better understand the mechanisms that determine antitumor immunity. Cancer‐specific neoantigens are considered key determinants of effective immune responses because they are recognized as non‐self by T cells and can induce strong immune responses. Accordingly, neoantigens are considered promising targets for cancer vaccines and adoptive cell therapies. Neoantigens have conventionally been considered to arise from somatic mutations and have been identified using whole‐exome sequencing (WES). However, the number of neoantigens identified with WES remains limited. In contrast, advances in technology have revealed that peptides derived from various sources, including noncoding regions, are immunogenic and function as neoantigens. In particular, human leukocyte antigen (HLA) ligandome analyses, which enabled the direct identification of peptides presented on HLA molecules in combination with various sequencing technologies, have extended the landscape of neoantigen sources. However, in many cases, the immunogenicity of the identified neoantigen candidates has not been experimentally evaluated. Recently, several experimental platforms have been developed to validate neoantigen immunogenicity, which can be complemented by single‐cell RNA/T‐cell receptor sequencing to identify tumor‐reactive T cell clones. In this review, we summarize current neoantigen identification strategies and discuss the challenges and future perspectives in neoantigen research.

Subjects

Author keywords

Antitumor immunityneoantigenproteogenomics

Authors and institutions

  • Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.
  • Department of Respiratory Medicine, Okayama University Hospital, Japan.
  • Faculty of Medicine, Kindai University, Osaka, Japan.

ORCID profiles: Yosuke Togashi

Funding

  • Fusion Oriented REsearch for disruptive Science and Technology
  • Canon Foundation for Scientific Research

Cite

APA

Ishino, T., & Togashi, Y. (2026). Modalities to identify clinically actionable neoantigens. The FEBS Journal. https://doi.org/10.1111/febs.70701

Vancouver

Ishino T, Togashi Y. Modalities to identify clinically actionable neoantigens. The FEBS Journal. 2026. doi:10.1111/febs.70701

BibTeX
@article{Ishino2026,
  author = {Ishino, Takamasa and Togashi, Yosuke},
  title = {Modalities to identify clinically actionable neoantigens},
  journal = {The FEBS Journal},
  year = {2026},
  doi = {10.1111/febs.70701}
}
Start for free →